While current treatment and liver transplantation strategies are reasonably effective for patients with early stage liver cancer, once the disease has advanced it becomes much harder to treat. Checkpoint immunotherapy has provided relief for some patients with advanced liver cancer, but the majority of patients still either don’t respond to the treatment or else develop resistance after initially responding. To address this, Dr. Guangchuan Wang is using a novel gene-editing approach to discover new factors that are responsible for resistance to immunotherapy. Identifying and validating the contribution of these factors will provide insights that could be used to improve immunotherapy approaches for liver cancer by helping doctors determine treatments might work best for which patients as well as highlighting novel targets for which future therapies could be developed.
Yale University | Liver Cancer | 2017 | Sidi Chen, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
CRI Fellow Dr. Tim Fessenden of MIT shared his day with the CRI social community on Friday, June 26.
CRI hosted esteemed immunologists Carl June, Miriam Merad, and E. John Wherry to highlight immunotherapy’s pivotal role in addressing the COVID-19 pandemic.